Dexcom expects that 15% of users in the new program will be eligible for prediabetes screening. The company plans to merge data collected from its Dexcom G7 and Stelo devices with additional metrics to offer a fuller health picture. This step supports Dexcom’s broader vision to use glucose monitoring for preventive care.
Digital health expansion
The new program tracks multiple health aspects, including diet, physical activity, sleep habits, and stress levels. These metrics, combined with glucose data, will help doctors track metabolic health across a patient population. The aim is to offer better, more proactive treatment tailored to individual needs.
AI as a chronic care tool
Jake Leach, president and CEO of Dexcom, emphasized the role of glucose in signaling early signs of health issues. He believes the data can be transformed to offer personalized and proactive care before chronic conditions progress. Leach sees the program as a key step in helping people make lifestyle changes before diseases take hold.
FDA's regulatory goals
The FDA's TEMPO pilot represents a new way to assess digital health tools while ensuring safety remains a priority. The goal is to accelerate the availability of innovative solutions for chronic disease. The program is part of the FDA's broader initiative to embrace digital advancements in healthcare without compromising patient well-being.
Dexcom highlighted the potential of the initiative to improve glycemic control and reduce HbA1c levels in people with prediabetes. The company hopes to gather real-world evidence showing how its AI-driven program can support early intervention and broader cardiometabolic research. By integrating data into a clinical framework, Dexcom aims to redefine how glucose monitoring contributes to disease prevention and management.
Being the first company invited to join the pilot underlines Dexcom’s leadership in digital glucose monitoring. The program could lead to new standards for using AI in chronic disease care. Dexcom is using this opportunity to expand access to its technology and demonstrate how digital tools can help prevent more serious health outcomes in the future.